NCT03362645
Diagnostic Value of the Electrocardiogram in Fabry Disease No drug interventions Not Available Not Available unknown_status NCT04724083
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy No drug interventions Not Available Not Available unknown_status NCT00437944
Relation Between Polymorphism in Genes Related to Kidney Disease and Renal Manifistations in Fabry Disease No drug interventions Not Available Not Available completed NCT01268241
The Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Patients With Anderson-Fabry Disease No drug interventions Not Available Not Available completed NCT05206773
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease treatment 3 recruiting NCT05280548
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease treatment 3 recruiting NCT05368038
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program No drug interventions Not Available Not Available enrolling_by_invitation NCT02994303
Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy No drug interventions Not Available Not Available unknown_status NCT00097890
Replagal Enzyme Replacement Therapy for Adults With Fabry Disease treatment 4 completed NCT03362164
Evaluation of HEArt invoLvement in Patients With FABRY Disease No drug interventions Not Available Not Available recruiting NCT00140621
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease treatment 4 completed NCT05046379
Studying Lipids as Potential Biomarkers in Patients With Fabry Disease No drug interventions Not Available Not Available completed NCT01650779
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta treatment 4 completed NCT03145779
Evaluation of Phenotypic Variability in Fabry Disease No drug interventions Not Available Not Available withdrawn NCT05054387
China Post-marketing Surveillance (PMS) Study of Fabrazyme® treatment 4 completed NCT00864851
Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease treatment 3 completed NCT00071877
An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease treatment 2 completed NCT01304277
This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes. other 2 completed NCT03596398
Epidemiological Study of Fabry Disease in Taiwan Young Stroke Patients No drug interventions Not Available Not Available unknown_status NCT06065605
Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease No drug interventions Not Available Not Available recruiting NCT01165697
Establishment of Biomarkers for Fabry Disease No drug interventions Not Available Not Available completed NCT03135197
German Observational Multicenter Study of Patients With Fabry Disease Under Chaperone Therapy With Migalastat-HCl. No drug interventions Not Available Not Available completed NCT00081497
A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease treatment 4 completed NCT01695161
Non-invasive Assessment of Intraocular Pressure in MPS by Use of the Ocular Response Analyzer. No drug interventions Not Available Not Available unknown_status NCT01632111
Pulmonary Involvement in Patients With Fabry Disease No drug interventions Not Available Not Available completed NCT03454893
Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease treatment 1 / 2 terminated NCT02995993
Pharmacokinetics, Pharmacodynamics, and Safety of Moss-aGalactosidase A in Patients With Fabry Disease basic_science 1 completed NCT01196871
Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease treatment 2 completed NCT06325488
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease No drug interventions Not Available Not Available not_yet_recruiting NCT00701415
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms treatment 3 completed NCT03838237
Effect of Migalastat on Cardiac Involvement in Fabry Disease No drug interventions Not Available Not Available completed NCT04050137
Therapeutic Exercise to Treat Neuropathic Pain No drug interventions treatment Not Available completed NCT06065852
National Registry of Rare Kidney Diseases No drug interventions Not Available Not Available recruiting NCT06207552
Evaluation of the Safety, Tolerability and Efficacy of a Gene Therapy Drug for the Treatment of Pediatric Fabry Disease No drug interventions treatment 0 recruiting NCT06052800
Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan No drug interventions Not Available Not Available recruiting NCT02969200
Fabry: Renal Function During Long-term ERT by 51Cr-EDTA Clearance Not Available Not Available completed NCT04856059
Fabry Cardiomyopathy: Identification of Early Myocardial Structural and Tissue Abnormalities Using Multiparametric MRI No drug interventions diagnostic Not Available recruiting NCT04999059
Long-Term Follow-up Study of Subjects With Fabry Disease Who Received Lentiviral Gene Therapy in Study AVRO-RD-01-201 No drug interventions Not Available Not Available terminated NCT01304875
Pulmonary Disease and Exercise Tolerance in Boys With Fabry Disease No drug interventions Not Available Not Available unknown_status NCT02800070
Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease treatment 1 completed NCT00233870
A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease. Not Available Not Available completed NCT00048906
Alpha-Galactosidase A Replacement Therapy for Fabry Disease treatment 2 completed NCT04974749
A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease treatment 3 completed NCT05056636
Epidemiological Study of Fabry Disease Screening in Chronic Kidney Disease Patients No drug interventions Not Available Not Available unknown_status NCT06095713
German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa Not Available Not Available recruiting NCT01458119
Open-Label Phase 3 Long-Term Safety Study of Migalastat treatment 3 terminated NCT03566017
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease treatment 3 active_not_recruiting NCT05761834
FASHION Fabry Disease Hypertrophic Cardiomyopathy and Infammation No drug interventions Not Available Not Available recruiting NCT01947634
Sleepiness and Sleep-disordered Breathing in Fabry Disease. A Prospective Cohort Study. No drug interventions diagnostic Not Available completed NCT00030134
Data Collection in Women With Fabry Disease No drug interventions Not Available Not Available completed NCT04046224
Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR) treatment 1 / 2 active_not_recruiting NCT01581424
Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study No drug interventions Not Available Not Available recruiting NCT05843916
Switch Over Study of Biosimilar AGA for Fabry Disease treatment 3 recruiting NCT01210196
Sophisticated Assessment of Disease Burden in Patients With Fabry Disease No drug interventions Not Available Not Available completed NCT06169358
Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy No drug interventions Not Available Not Available recruiting NCT02859363
Fabry Disease in Cerebrovascular Disease No drug interventions Not Available Not Available unknown_status NCT01476163
Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease Not Available Not Available approved_for_marketing NCT00357786
An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease treatment 1 completed NCT02023086
Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Fabry Patients Not Available Not Available completed NCT04184986
Screening of Fabry Disease in Patients With GI Symptoms No drug interventions Not Available Not Available unknown_status NCT00487630
Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease treatment 4 unknown_status NCT01839526
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease basic_science 1 terminated NCT06303466
Real World Evidence Study of Danish Fabry Patients No drug interventions Not Available Not Available active_not_recruiting NCT03683966
MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study No drug interventions Not Available Not Available unknown_status NCT04252066
A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding Not Available Not Available recruiting NCT00001774
Vasodilation in Patients With Fabry's Disease No drug interventions Not Available Not Available completed NCT03949920
A Study of Migalastat in Fabry Disease Not Available Not Available active_not_recruiting NCT05413876
Fabry Exercise Intolerance Study No drug interventions Not Available Not Available recruiting NCT02795676
Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function treatment 3 completed NCT02228460
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease No drug interventions treatment 2 completed NCT03500094
Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years) treatment 3 completed NCT04943991
Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical Score No drug interventions screening Not Available active_not_recruiting NCT00446862
The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study Not Available Not Available completed NCT06114329
Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease treatment 2 recruiting NCT01997489
Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients. treatment 4 completed NCT04893889
Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease. No drug interventions diagnostic Not Available unknown_status NCT01363492
Safety Study of Replagal® Therapy in Children With Fabry Disease treatment 2 completed NCT02489344
Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease No drug interventions treatment 2 completed NCT00075244
Alternative Dosing and Regimen of Replagal to Treat Fabry Disease treatment 2 completed NCT03180840
Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks treatment 3 completed NCT03228940
Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease treatment 1 / 2 withdrawn NCT00312767
A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency. treatment 4 withdrawn NCT05710367
Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients treatment 2 not_yet_recruiting NCT04025801
Heidelberg In Vivo Confocal Microscopy to Evaluate the Ocular Surface Disorders of Healthy and Diseased Individuals No drug interventions Not Available Not Available unknown_status NCT04189601
Complement Activation in the Lysosomal Storage Disorders No drug interventions Not Available Not Available withdrawn NCT06007768
Autoimmune and Inflammatory Response Biomarkers in Fabry Disease No drug interventions Not Available Not Available recruiting NCT05409846
Screening of Fabry Disease in Portuguese Patients With Idiopathic Cardiomyopathies No drug interventions Not Available Not Available recruiting NCT02985710
Assessment of Small Fiber Neuropathy in Rare Diseases Using Sudoscan No drug interventions diagnostic Not Available completed NCT03886714
Screening for Fabry Disease in Renal Transplantation No drug interventions Not Available Not Available recruiting NCT03737214
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease treatment 3 active_not_recruiting NCT01588314
Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease treatment 2 withdrawn NCT04020055
A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease treatment 3 recruiting NCT03305250
Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry Disease No drug interventions diagnostic Not Available active_not_recruiting NCT03123523
Study of the Relation Between Lipid Myocardial Overload Evaluated by Cardiac Magnetic Resonance Imaging (MRI), Alteration of Longitudinal Myocardial Deformations by Echocardiography, and Clinical Achievements (Functional, Biological and Electrical) in Fabry Disease, and Its Outcomes. No drug interventions Not Available Not Available unknown_status NCT02090608
Paricalcitol in Fabry Disease treatment Not Available completed NCT01295008
Androgenetic Alopecia in Fabry Disease No drug interventions Not Available Not Available completed NCT05106764
Early Detection of Fabry Disease No drug interventions Not Available Not Available active_not_recruiting NCT04602364
French Prospective, Observational Cohort Study of Patients With Fabry Disease Treated With Migalastat No drug interventions Not Available Not Available completed NCT00084084
Replagal Enzyme Replacement Therapy for Children With Fabry Disease treatment 2 completed NCT00074984
A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease treatment 4 completed NCT00283933
A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease treatment 2 completed NCT04440254
Long Duration Holter ECG in Fabry Disease No drug interventions screening Not Available not_yet_recruiting NCT00343577
Antiproteinuric Agents and Fabry Disease No drug interventions Not Available Not Available completed NCT04916977
Global Burden and Treatment Trajectiories in Italian Patients With Fabry Disease No drug interventions Not Available Not Available completed NCT01678898
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients treatment 1 / 2 completed NCT01374997
Detection of Fabry Disease in Chronic Renal Failure Patients in Area Provence - Alpes - Côte d'Azur No drug interventions diagnostic Not Available completed NCT00871611
Viennese Prevalence Study of Anderson-Fabry Disease No drug interventions Not Available Not Available unknown_status NCT00005111
PET Scans in Normal Volunteers and Patients With Fabry Disease No drug interventions Not Available Not Available completed NCT00526071
Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study treatment 2 terminated NCT00074971
A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease treatment 3 completed NCT06484478
A Real-world Wearables Study in Fabry Disease. No drug interventions Not Available Not Available not_yet_recruiting NCT04073888
Study of the Spermatic Characteristics of Patients With Fabry Disease No drug interventions diagnostic Not Available completed NCT05923788
T1 Mapping in Fabry Disease No drug interventions diagnostic Not Available recruiting NCT00068107
Dosing Study of Replagal in Patients With Fabry Disease treatment 2 completed NCT00230607
Study of the Effects of Fabrazyme Treatment on Lactation and Infants treatment 4 terminated NCT01745185
Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta No drug interventions Not Available Not Available completed NCT02194985
Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease treatment 3 completed NCT05343715
PK/PD Study of 2 Agalsidase Formulations in Single Dose of 1 mg/kg Administered to Healthy Volunteers as IV Infusion treatment 1 completed NCT05473637
Taiwan Associated Genetic and Nongenetic Small Vessel Disease No drug interventions Not Available Not Available recruiting NCT04281537
A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy. Not Available Not Available completed NCT01853852
A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects No drug interventions Not Available 1 completed NCT00214500
A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease treatment 2 completed NCT00283959
A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease treatment 2 completed NCT01218659
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease treatment 3 completed NCT05629559
4D-310 in Adults With Fabry Disease and Cardiac Involvement treatment 1 / 2 active_not_recruiting NCT04577170
Pulsatility Index, Vasomotor Reactivity and Leukoencephalopathy in Fabry Patients No drug interventions Not Available Not Available completed NCT05671770
Study Based on Electronic Health RecOrds to Identify Patients at High-risk of Fabry DiseasE (HOPE Fabry) No drug interventions Not Available Not Available completed NCT00196742
Fabry Disease Registry & Pregnancy Sub-registry No drug interventions Not Available Not Available recruiting NCT04639999
Impact of MIgalastat TheRApy on CaRdiac Function in patiEnts With Fabry's Cardiomyopathy (MIRACRE-Fabry Trial) No drug interventions Not Available Not Available recruiting NCT04519749
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease treatment 1 / 2 active_not_recruiting NCT04040049
A Fabry Disease Gene Therapy Study No drug interventions treatment 1 / 2 terminated NCT03230149
Prevalence and Characteristics of Fabry Disease (FD) in Patients With Stroke or Small Fiber Neuropathy No drug interventions Not Available Not Available completed NCT00149318
Enzyme Replacement Therapy in Fabry Disease No drug interventions Not Available Not Available terminated NCT01298141
A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease treatment 3 completed NCT02843334
Study of the Prevalence of Fabry Disease in French Dialysis Patients No drug interventions Not Available Not Available unknown_status NCT03614234
Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients treatment 3 active_not_recruiting NCT03678324
Pre-Clinical White Matter Changes and Associated Connectivity Effects in Fabry Disease No drug interventions basic_science Not Available completed NCT02908724
Cardiac Involvement in Adult Patients With Fabry Disease; Relation to Enzyme Replacement Therapy No drug interventions Not Available Not Available completed NCT06539624
Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease No drug interventions treatment Not Available not_yet_recruiting NCT00837824
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme treatment 2 terminated NCT05186324
Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly Infusion No drug interventions Not Available Not Available completed NCT06270316
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease No drug interventions treatment 1 / 2 recruiting NCT00196716
A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease treatment 2 completed NCT00055016
Registry of Fabry Disease - A Multicenter Observational Study No drug interventions Not Available Not Available completed NCT00074958
A Study of Fabrazyme in Pediatric Patients With Fabry Disease treatment 2 completed NCT04143958
To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease treatment 4 withdrawn NCT02120235
Investigating Lysosomal Storage Diseases in Minority Groups No drug interventions Not Available Not Available unknown_status NCT03425539
Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease treatment 3 completed NCT04455230
A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190 No drug interventions other 1 / 2 completed NCT03018730
Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa) treatment 3 completed NCT04758130
Getting Global Rare Disease Insights Through Technology Study No drug interventions other Not Available unknown_status NCT04804566
Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients No drug interventions Not Available Not Available completed NCT05039866
Long-Term Follow-up of Subjects Who Were Treated With ST-920 Not Available Not Available enrolling_by_invitation NCT05699265
Cardiovasculorenal Phenotyping in Fabry Disease Through Noninvasive Testing No drug interventions Not Available Not Available recruiting NCT03289065
Fabry Outcome Survey (FOS) No drug interventions Not Available Not Available completed NCT00168974
Neuropathic Pain and Fabry Disease No drug interventions Not Available Not Available completed NCT01981720
Extension Study of PRX-102 for up to 60 Months treatment 1 / 2 completed NCT02921620
Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease treatment 3 withdrawn NCT01730482
A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014) No drug interventions treatment 1 completed NCT01031173
Treatment Protocol of Replagal for Patients With Fabry Disease Not Available Not Available no_longer_available NCT04043273
Treatment-related Benefit and Satisfaction in Fabry Patients. Insight in Patients Expectations and Preferences No drug interventions Not Available Not Available completed NCT02082327
A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers treatment 1 completed NCT05679076
A Qualitative Study on the Pain and Quality of Life of Patients With Fabry Disease No drug interventions Not Available Not Available recruiting NCT02649660
Lipidomics and Functional Analyses of Platelets in Fabry Disease No drug interventions Not Available Not Available unknown_status NCT04049760
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease treatment 3 active_not_recruiting NCT04552691
Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients Not Available Not Available approved_for_marketing NCT03230591
Impact of Agalsidase Alfa Therapy on Cardiac funcTION in Patients With Fabry's Cardiomyopathy No drug interventions Not Available Not Available recruiting NCT06081062
Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease treatment 3 recruiting NCT01019629
Fabry Screening Study No drug interventions Not Available Not Available completed NCT02152189
Screening for Fabry Disease in a Pediatric Population at Risk No drug interventions Not Available Not Available completed NCT05710692
Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease treatment 2 / 3 recruiting NCT01653444
Evaluate the Safety and Exploratory Efficacy of GC1119 No drug interventions treatment 1 completed NCT04840667
A Study of Replagal in Treatment-naïve Adults With Fabry Disease treatment 3 terminated NCT04965467
Fabry Aim Children Early (ACE) Project No drug interventions Not Available Not Available withdrawn NCT03199001
Native T1 Mapping by Cardiovascular Magnetic Resonance Imaging in Rare Diseases No drug interventions Not Available Not Available unknown_status NCT06257901
A Co-designed Physical Activity Intervention in Fabry Disease No drug interventions Not Available Not Available active_not_recruiting NCT04708301
Characterisation of Heart Involvement in Fabry Disease With T1 Mapping No drug interventions Not Available Not Available completed NCT05698901
Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease Not Available Not Available recruiting NCT00925301
Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease treatment 3 completed NCT03321604
Kidney Information Network for Disease Research and Education No drug interventions Not Available Not Available terminated NCT00455104
Canadian Fabry Disease Initiative (CFDI) National Registry No drug interventions Not Available Not Available recruiting NCT05067868
A Study of Replagal in Children and Adults With Fabry Disease in India treatment 4 active_not_recruiting NCT01730469
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function treatment 1 completed NCT01355146
Home Therapy With Replagal in Fabry Disease No drug interventions Not Available Not Available completed NCT00304512
A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease treatment 2 completed NCT00106912
Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity No drug interventions Not Available Not Available completed NCT00413595
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation No drug interventions Not Available Not Available completed NCT01489995
Migalastat Food Effect Study treatment 1 completed NCT02930655
A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease treatment 1 completed NCT06328608
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease treatment 2 / 3 not_yet_recruiting NCT01124643
Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease treatment 3 completed NCT01769001
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients treatment 1 / 2 completed NCT01178164
Prevalence of Fabry's Disease in a Population of Patients With Chronic Pains No drug interventions diagnostic Not Available completed NCT04847713
Early Detection and Follow-Up of Patients With Fabry's Disease No drug interventions Not Available Not Available unknown_status NCT02469181
Impact of Enzyme Replacement Therapy on Cardiac Function in Patients With Fabry's Cardiomyopathy (RECAFTURE Trial) No drug interventions Not Available Not Available recruiting NCT06019728
A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme treatment 4 recruiting NCT02798458
Evaluation of the Gastrointestinal Manifestation of Fabry's Disease No drug interventions diagnostic Not Available completed NCT02582294
Fabry's Disease and Pregnancy (PREFAB) No drug interventions Not Available Not Available terminated NCT00001491
Analysis of the Nervous System in Patients With Fabry's Disease No drug interventions Not Available Not Available completed NCT02450604
Prevalence of Fabry's Disease in a Population of Patients With Chronic Pain No drug interventions diagnostic Not Available completed